Table 1.

Clinical Details of Patients and Somatic Variants in Discovery Set of 7 Pituitary NFAs^a

Patient			Tumor
Tumor Number	Age, y	Sex	Tumor Volume, cm3b	Histologyc	Ki-67 Index	Number of Somatic Variants
1	64	M	15.9	GA (FSH 70%, LH 15%)	2–3%	2
2	59	M	9.1	GA (FSH 5–10%)	2–3%	7
3	59	M	4.2	GA (FSH 15%)	2%	5
4	42	F	0.7	GA (FSH 30%)	2%	5
5	82	F	2.4	GA (FSH 20–30%)	1–2%	1
6	36	F	2.2	GA (LH 5%)	2–3%	2
7	40	M	9.0	GA (FSH 60%, LH 2%)	2–3%	2

Abbreviation: GA, gonadotroph adenoma (immunostaining for LH and/or FSH).

^aSeven samples were used in the discovery set for exome capture and sequencing studies because power calculations indicated that this number would be able to identify common driver mutations with a greater than 90% probability of identifying 1 or more mutations in genes involved in 30% of tumors (Varela I, Tarpey P, Raine K, Huang D, Ong CK, Stephens P, et al. Nature 2011;469:539–542).

^bEstimated tumor volume using the Di Chiro-Nelson method of V = 1/2(h × w × l) as documented on preoperative magnetic resonance imaging.

^cNone of the pituitary NFAs had features of atypia.